Role of Radiation in Treatment of Renal Cell Carcinoma.
Immunotherapy
Oligometastatic
Radiosensitivity
Radiotherapy
Renal cell carcinoma
Stereotactic body radiation therapy
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
18
9
2023
pubmed:
29
5
2023
entrez:
28
5
2023
Statut:
ppublish
Résumé
Initial studies of radiotherapy in renal cell carcinoma (RCC) failed to demonstrate significant clinical impact. With the advent of stereotactic body radiotherapy (SBRT) that allows for delivery of more effective radiation doses in a precise fashion, radiotherapy has become an essential component in the multidisciplinary management of patients with RCC both in the setting of localized and metastatic disease beyond the traditional role of palliative treatment. Recent evidence has demonstrated high rates of long-term local control (∼95%) when SBRT is delivered to kidney tumors with limited toxicity risks and only minor impact on renal function.
Identifiants
pubmed: 37246085
pii: S0889-8588(23)00049-7
doi: 10.1016/j.hoc.2023.04.015
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
921-924Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.